Philips-Biocartis deal
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics developer Biocartis will acquire Philips' rapid, fully-automated DNA/RNA molecular diagnostic testing platform under an agreement announced Feb. 10. Potential applications include oncology and infectious disease testing. Financial terms of the agreement were not disclosed